Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
17,38 USD | -5,54% | -14,51% | +62,43% |
15/04 | IMMUNOME, INC. : Guggenheim handhaaft koopadvies | ZM |
01/04 | IMMUNOME, INC. : Wedbush herhaalt koopadvies | ZM |
Omzet 2024 * | 8 mln. 7,49 mln. | Omzet 2025 * | - | Marktkapitalisatie | 1,04 mld. 971 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -114 mln. -107 mln. | Nettowinst (verlies) 2025 * | -149 mln. -139 mln. | EV/omzet 2024 * | 130 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-8,69
x | K/w-verhouding 2025 * |
-7,32
x | Werknemers | 55 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 81,9% |
1 dag | -5,54% | ||
1 week | -14,51% | ||
Lopende maand | -29,58% | ||
1 maand | -22,69% | ||
3 maanden | +24,14% | ||
6 maanden | +98,63% | ||
Lopend jaar | +62,43% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 64 | 02-10-23 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 02-10-23 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 02/01 |
Director/Board Member | 70 | 07/11 | |
Clay Siegall
CEO | Chief Executive Officer | 64 | 02-10-23 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
17-04-24 | 17,38 | -5,54% | 959 246 |
16-04-24 | 18,4 | -2,39% | 881 761 |
15-04-24 | 18,85 | -8,41% | 719 028 |
12-04-24 | 20,58 | -2,09% | 305 366 |
11-04-24 | 21,02 | +3,39% | 374 799 |
uitgestelde koers Nasdaq, 17 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+62,43% | 1,04 mld. | |
-3,39% | 102 mld. | |
+2,61% | 96,84 mld. | |
-1,02% | 21,48 mld. | |
-18,14% | 20,82 mld. | |
-6,87% | 18,6 mld. | |
-40,70% | 16,81 mld. | |
-26,89% | 13,78 mld. | |
+1,12% | 13,4 mld. | |
+22,25% | 11,06 mld. |